From the publishers of JADPRO

MPN Resource Center

Advertisement

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine

Last Updated: Tuesday, April 11, 2023

Data from a prospective study of 43 patients with either myelofibrosis or polycythemia vera receiving ruxolitinib showed that 32.5% did not develop any response after two SARS-CoV-2 mRNA vaccine boosters. After a third booster, 80% produced antibodies above the threshold positivity, yet still well below that reported for healthy individuals.

Frontiers in Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement